Our pipeline features groundbreaking therapies in development to address anxiety, PTSD, and other neuropsychiatric disorders. Each program reflects our commitment to advancing science and transforming patient care.
BNC210, a novel negative allosteric modulator of the α7 nicotinic acetylcholine receptor, targets glutamatergic hyperactivity in brain regions linked to stress, anxiety, and mood disorders, such as the amygdala and prefrontal cortex. Preclinical studies show anti-anxiety, anti-stress, and antidepressant effects, along with improved fear extinction, highlighting its potential for PTSD treatment.
PTSD is a chronic condition triggered by severe trauma, including combat, childhood abuse, or sexual violence. It manifests as intrusive memories, nightmares, severe anxiety, hypervigilance, depression, and emotional withdrawal, severely impacting daily life and well-being.
Social Anxiety Disorder is marked by intense fear of social or performance situations, especially involving unfamiliar people or potential scrutiny. It can range from fear of public speaking to discomfort in everyday social interactions.
Panic Disorder:
Generalized Anxiety Disorder (GAD):
BNC210, a novel negative allosteric modulator of the α7 nicotinic acetylcholine receptor, targets glutamatergic hyperactivity in brain regions linked to stress, anxiety, and mood disorders, such as the amygdala and prefrontal cortex. Preclinical studies show anti-anxiety, anti-stress, and antidepressant effects, along with improved fear extinction, highlighting its potential for PTSD treatment.
In 2014, Neuphoria partnered with MSD (Merck & Co., Inc., USA) through an exclusive Research Collaboration and License Agreement to develop α7 Receptor PAMs for treating cognitive dysfunction in Alzheimer’s disease and other CNS disorders.
BNC375: The original lead molecule demonstrated robust, dose-dependent efficacy across multiple cognitive animal models.
MK-1167: MSD’s novel clinical candidate has shown improved drug-like and pharmacological properties in preclinical studies compared to BNC375.
These compounds show potential for restoring memory function in conditions such as Alzheimer’s, schizophrenia, and ADHD. In animal studies, they have demonstrated effectiveness across various learning and memory models with a strong safety profile.
Clinical studies, including Phase 1 trials and biomarker evaluations, have highlighted the promise of α7 nAChR PAMs, with the program set to enter Phase 2 clinical development soon.
We advanced our oncology program, BNC101, targeting cancer stem cells, through external funding and out-licensing to create shareholder value. BNC101, a humanized monoclonal antibody targeting LGR5, a receptor overexpressed in solid tumors, was exclusively licensed to Carina Biotech in November 2020 for CAR-T therapy development.
Carina’s LGR5-targeted CAR-T therapy, CNA3103, is in Phase 1/2a trials for metastatic colorectal cancer, with patient dosing beginning in December 2023. Under the agreement, Bionomics may earn up to AUS$118 million in milestone payments plus royalties.
Utilizing our expertise in ion channel biology and translational medicine, we are developing next generation orally bioavailable small molecule series of negative allosteric modulators (NAMs) targeting that the α7 nicotinic acetylcholine receptor that can be potentially positioned for the treatment of additional neuropsychiatric disorders of high unmet clinical need.
Kv3.1/Kv3.2 voltage gated potassium channels are involved in regulating cognitive function and social interaction. Pharmacological activation of Kv3.1/Kv3.2 channels may possess therapeutic potential for treatment of cognitive disorders. In preclinical models our series of small molecule Kv3.1/3.2 potassium channel agonists have been associated with the reversal of pharmacologically induced cognitive deficits.
Discover how our groundbreaking technology is transforming mental health—contact us today to learn more.